Press releases

2008

12/12/2008
ABLYNX REPORTS POSITIVE PHASE Ib RESULTS FOR ITS ANTI-THROMBOTIC NANOBODY® ALX-0081


10/12/2008
ABLYNX REACHES MILESTONE IN TNF-alpha NANOBODY® COLLABORATION AS WYETH PHARMACEUTICALS INITIATES PHASE I


08/12/2008
ABLYNX EXPANDS ITS ANTI-THROMBOTIC PORTFOLIO AND ANNOUNCES INITIATION OF A PHASE I STUDYFOR ALX-0681


19/11/2008
ABLYNX PROVIDES A BUSINESS UPDATE FOR THE THIRD QUARTER 2008


05/11/2008
ABLYNX NV - TRANSPARENCY NOTIFICATION


20/10/2008
ABLYNX SECURES NEW FACILITIES TO SUPPORT LONG-TERM GROWTH


10/10/2008
ABLYNX PROVIDES AN R&D UPDATE ANNOUNCING IT HAS SUCCESSFULLY GENERATED NANOBODIES® AGAINST GPCRs AND PRESENTS NEW PRECLINICAL DEVELOPMENT RANKL PROGRAMME


03/10/2008
ABLYNX IS AWARDED €1.8 MILLION GRANT TO EXPLORE NOVEL METHODS FOR USES OF NANOBODIES®


12/09/2008
PUBLICATION IN ACCORDANCE WITH THE ACT OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS


04/09/2008
ABLYNX AND MERCK SERONO ENTER INTO AN AGREEMENT TO CO-DISCOVER AND CO-DEVELOP NANOBODIES®


28/08/2008
ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2008


21/08/2008
ABLYNX WILL ANNOUNCE HALF YEAR RESULTS FOR 2008 ON 28 AUGUST 2008


21/08/2008
BOEHRINGER INGELHEIM EXTENDS RESEARCH COLLABORATION WITH ABLYNX FOR ALZHEIMER'S DISEASE


28/05/2008
ABLYNX ANNOUNCES INITIATION OF A PHASE IB STUDY IN PATIENTS FOR ALX-0081 AND PROVIDES A BUSINESS UPDATE FOR THE FIRST QUARTER 2008


27/04/2008
ABLYNX ANNOUNCES SENIOR MANAGEMENT CHANGE


28/02/2008
ABLYNX ANNOUNCES FULL YEAR RESULTS FOR 2007


21/02/2008
ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2007 ON 28 FEBRUARY 2008


19/02/2008
ABLYNX RECEIVES MILESTONE PAYMENT FROM NANOBODY® DISCOVERY AND DEVELOPMENT ALLIANCE


05/02/2008
ABLYNX RESPONDS TO REQUEST FOR ARBITRATION FROM DOMANTIS